Lantheus Financial Statements
NASDAQ: LNTHHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
Market open · Delayed 15 min · as of Oct 9, 3:43 PM ET
Lantheus revenue and earnings
In fiscal 2025, Lantheus generated $1.54 billion in revenue, up 0.5% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $233.6 million (-25.2% year over year), for a net margin of 15.2% versus a median of 3.0% in the prior 5 years. Gross margin was 61.1% (down from 64.4%) and operating margin 20.2%.
Diluted earnings per share came in at $3.41, down from $4.36. Over the last 5 fiscal years, LNTH's revenue has grown at a 35.3% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Lantheus income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.54B | 1.53B | 1.30B | 935.06M | 425.21M | 339.41M | 347.34M | 343.37M | 331.38M | 301.85M |
| Revenue growth (YoY) | +0.50% | +18.32% | +38.65% | +119.91% | +25.28% | -2.28% | +1.15% | +3.62% | +9.78% | +2.86% |
| Cost of Revenue | 599.66M | 545.62M | 586.89M | 353.36M | 237.51M | 200.65M | 172.53M | 168.49M | 169.24M | 164.07M |
| Gross Profit | 941.95M | 988.29M | 709.54M | 581.70M | 187.69M | 138.76M | 174.81M | 174.88M | 162.13M | 137.78M |
| Operating Expenses | 631.12M | 531.31M | 344.90M | 545.51M | 248.52M | 142.96M | 123.15M | 110.40M | 110.28M | 81.19M |
| Research & Development | 177.31M | 168.10M | 77.71M | 311.68M | 44.97M | 32.79M | 20.02M | 17.07M | 18.13M | 12.20M |
| Selling, General & Admin | 453.81M | 371.63M | 267.19M | 233.83M | 218.82M | 110.17M | 103.13M | 93.33M | 92.16M | 75.37M |
| Operating Income | 310.83M | 456.98M | 364.64M | 36.20M | -60.83M | -4.20M | 51.66M | 64.49M | 51.85M | 56.59M |
| Interest Expense | 19.75M | 19.67M | 20.02M | 7.18M | 7.75M | 9.48M | 13.62M | 17.41M | 18.41M | 26.62M |
| Other Income (Expense) | 31.33M | 37.23M | 66.32M | -1.70M | -7.35M | 2.20M | -6.22M | 2.46M | 8.64M | 220.00K |
| Pretax Income | 313.79M | 430.98M | 410.94M | 26.72M | -75.04M | -11.48M | 28.63M | 49.55M | 39.64M | 28.29M |
| Income Tax | 80.23M | 118.53M | 84.28M | -1.35M | -3.76M | 1.99M | -3.04M | 9.03M | -83.75M | 1.53M |
| Net Income | 233.56M | 312.44M | 326.66M | 28.07M | -71.28M | -13.47M | 31.67M | 40.52M | 123.39M | 26.76M |
| Net Income growth (YoY) | -25.25% | -4.35% | +1063.86% | — | — | -142.55% | -21.84% | -67.16% | +361.05% | — |
| EPS (Basic) | 3.46 | 4.52 | 4.79 | 0.41 | -1.06 | -0.25 | 0.81 | 1.06 | 3.31 | 0.84 |
| EPS (Diluted) | 3.41 | 4.36 | 4.65 | 0.40 | -1.06 | -0.25 | 0.79 | 1.03 | 3.17 | 0.82 |
| Shares Outstanding (Basic) | 67.49M | 69.20M | 68.27M | 68.49M | 67.49M | 54.13M | 38.99M | 38.23M | 37.28M | 32.04M |
| Shares Outstanding (Diluted) | 68.44M | 71.65M | 70.24M | 70.67M | 67.49M | 54.13M | 40.11M | 39.50M | 38.89M | 32.66M |
| EBITDA | 380.93M | 521.60M | 424.69M | 84.12M | -18.54M | 20.49M | 65.04M | 78.42M | 71.08M | 74.85M |
| Gross Margin | 61.10% | 64.43% | 54.73% | 62.21% | 44.14% | 40.88% | 50.33% | 50.93% | 48.93% | 45.64% |
| Operating Margin | 20.16% | 29.79% | 28.13% | 3.87% | -14.30% | -124.00% | 14.87% | 18.78% | 15.65% | 18.75% |
| Net Margin | 15.15% | 20.37% | 25.20% | 3.00% | -16.76% | -3.97% | 9.12% | 11.80% | 37.23% | 8.87% |
This table shows 10 annual periods of Lantheus's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow LNTH's reporting calendar. What is a income statement?